Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study

by Wei Xu, Shenmiao Yang, Keshu Zhou, Ling Pan, Zengjun Li, Jianfeng Zhou, Sujun Gao, Daobin Zhou, Jianda Hu, Ru Feng, Haiwen Huang, Meng Ji, Haiyi Guo, Jane Huang, William Novotny, Shibao Feng, Jianyong Li
Published 2020-05-01

791 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL)

by Hui Zhou, Jun Zhu, Xiaoling Li, Fei Li, Lei Fan, Lihong Liu, Zheng Zhao, Bing Chen, Qingyuan Zhang, Yuqin Song, Keshu Zhou, Chuan Jin, Zhengzi Qian, Ming Hou, Kaiyang Ding, Xiuhua Sun, Xianmin Song, Ming Jiang, Yu Hu, Ligen Liu, Hongwei Xue, Jun Luo, Bai He, Maxwell Wang
Published 2020-11-01